J. Theiler

Neutralization Escape by SARS-CoV-2 Omicron Subvariant BA.2.86

This study evaluates the neutralization escape of the SARS-CoV-2 Omicron subvariant BA.2.86 compared to other variants, finding lower neutralization by antibodies than BA.2 but comparable to circulating variants.

Mutational basis of serum cross-neutralization profiles elicited by infection or vaccination with SARS-CoV-2 variants

The paper models cross-neutralization profiles of SARS-CoV-2 sera against variants by analyzing mutations and shows that a third dose of mRNA-1273 improves neutralization breadth.

Substantial Neutralization Escape by the SARS-CoV-2 Omicron Variant BQ.1.1

The paper shows BQ.1.1 SARS-CoV-2 variant has greater neutralization escape compared to BA.5, with lower NAb titers in vaccinated individuals.

Characterization of SARS-CoV-2 Omicron BA.2.75 clinical isolates

This study evaluates the replicative ability and pathogenicity of SARS-CoV-2 BA.2.75 isolates in Syrian hamsters, finding higher lung replication and focal pneumonia compared to BA.2 and BA.5.

SARS-CoV-2 variant B.1.1.7 is susceptible to neutralizing antibodies elicited by ancestral Spike vaccines

This study shows that B.1.1.7 SARS-CoV-2 variant remains neutralizable by antibodies from ancestral Spike vaccines and convalescent sera, though with reduced efficacy.

Durable Control of HIV-1 Using a Staphylococcus aureus Cas9-Expressing Lentivirus Co-Targeting Viral Latency and Host Susceptibility

This study develops a lentiviral vector targeting both HIV-1 provirus and host CXCR4 to reduce gene editing efficacy thresholds for an HIV-1 cure.

Spike mutation pipeline reveals the emergence of a more transmissible form of SARS-CoV-2

The paper develops a pipeline to track SARS-CoV-2 mutations in the Spike protein, identifying D614G as a rapidly spreading mutation with potential implications for transmission and immune evasion.